title: Pleuropulmonary and lymph node progression after docetaxel - benefits from treatment with cabazitaxel in metastatic prostate cancer.
abstract: BACKGROUND
  To date, there are no guidelines for a rational and more favourable sequence of treatment after docetaxel. Two drugs (cabazitaxel and abiraterone) have recently been approved as second-line treatment after docetaxel failure in metastatic castration-resistant prostate cancer (mCRPC), but there are no studies comparing abiraterone versus cabazitaxel. The most suitable drug is chosen based on the physician's opinion and the patient's characteristics. In patients with a good performance status who are able to receive either treatment, it would be convenient to begin with cabazitaxel and to reserve abiraterone in case there is a worsening of the general status, in consideration of abiraterone's more favourable toxicity profile.
  
  
  METHODS
  We describe the case of a 74-year-old male with mCRPC who presented with an interesting and uncommon tumour dissemination (pleuropulmonary) occurring after the first standard treatment with docetaxel. Intravenous treatment with cabazitaxel 25 mg/m(2) and oral prednisone 10 mg continuously was initiated. The patient received a total of 8 cycles of chemotherapy. A reduction of mediastinal adenopathies and infrarenal para-aortic stable bone involvement and an absence of pleural effusion were observed. No relevant toxicity was noted. Since February 2012, a progressive PSA increase without clinical deterioration has been noted.
  
  
  CONCLUSIONS
  The selection criteria for second- and third-line systemic treatment and the excellent response obtained with cabazitaxel in an unusual disease setting are described. The results confirm the long duration and quality of response of cabazitaxel treatment. Further therapeutic options in this group of patients are suggested.
authors.affiliation: Medical Oncology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain.
authors.forename: Angel Segura
authors.initials: AS
authors.lastname: Huerta
authors.forename: Encarnación Reche
authors.initials: ER
authors.lastname: Santos
authors.forename: Gema Bruixola
authors.initials: GB
authors.lastname: Campos
authors.forename: Carmen Salvador
authors.initials: CS
authors.lastname: Coloma
authors.forename: Oscar Niño
authors.initials: ON
authors.lastname: Gómez
keywords: Cabazitaxel; Castration-resistant prostate cancer; Pleuropulmonary progression
references.citation: Ann Oncol. 2006 Jun;17(6):986-9
references.pmid: 16533874
references.citation: J Clin Oncol. 2009 Jun 10;27(17):2766-71
references.pmid: 19380448
references.citation: J Clin Oncol. 2002 Oct 1;20(19):3972-82
references.pmid: 12351594
references.citation: J Clin Oncol. 2007 Nov 20;25(33):5313-8
references.pmid: 17925542
references.citation: Oncol Rep. 2008 Oct;20(4):891-6
references.pmid: 18813832
references.citation: N Engl J Med. 2011 May 26;364(21):1995-2005
references.pmid: 21612468
references.citation: Lancet. 2010 Oct 2;376(9747):1147-54
references.pmid: 20888992
references.citation: Eur J Cancer. 2014 Apr;50(6):1090-9
references.pmid: 24485664
references.citation: Br J Cancer. 2004 Jun 14;90(12):2317-25
references.pmid: 15150570
references.citation: J Urol. 2001 Jan;165(1):136-40
references.pmid: 11125382
references.citation: J Natl Cancer Inst. 2002 Oct 2;94(19):1458-68
references.pmid: 12359855
references.citation: J Clin Oncol. 2009 May 20;27(15):2450-6
references.pmid: 19380444
references.citation: Curr Opin Urol. 2011 May;21(3):241-7
references.pmid: 21455038